Home Neoplasma 2012 Neoplasma Vol.59, No.3, p.282-288, 2012

Journal info

6 times a year.
Founded: 1954
ISSN 0028-2685
ISSN 1338-4317 (online)

Published in English

Editorial Info
Abstracted and Indexed
Submission Guidelines

Select Journal

Webshop Cart

Your Cart is currently empty.

Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.

Neoplasma Vol.59, No.3, p.282-288, 2012

Title: A subpopulation of CD24+ cells in colon cancer cell lines possess stem cell characteristics
Author: J. KE, X. WU, X. WU, X. HE, L. LIAN, Y. ZOU, X. HE, H. WANG, Y. LUO, L. WANG, P. LAN

Abstract: Cancer stem cells (CSCs) have been shown to contribute to the resistance and relapse in a range of cancer types such as breast cancer and glioma. However, colon cancer stem cells remain poorly characterized. Here we reported that CD24+ subpopulation in colon cancer cell lines HCT116 and SW480 exhibited cancer stem cell-like characteristics. Using flow cytometry candidate CSCs markers were selected after initial screening of known CSCs markers from other types of cancer on colon cancer cell lines HCT116, SW480 and HT29. CD24 was expressed in the minority of bulk cell population of HCT116 and SW480 cell lines. Moreover, functional tests demonstrated that CD24+ cells exhibited enhanced chemotherapy-resistance, self-renewal and tumorigenic capacity both in vitro and in vivo, compared to CD24– subpopulations. These results suggest that CD24+ subpopulation in colon cancer cell lines HCT116 and SW480 exhibits CSCs like characteristics, and represents a nice model to study and develop effective strategies to overcome chemo-resistance and relapse of colon cancer.

Keywords: CD24, colon cancer, cancer stem cell, self-renewal, stem cell marker
Received: 19-Oct-2011 Published online: 13-Feb-2012
Year: 2012, Volume: 59, Issue: 3 Page From: 282, Page To: 288

download file

© AEPress s.r.o
Copyright notice: For any permission to reproduce, archive or otherwise use the documents in the ELiS, please contact AEP.